SANION

Saniona

Research note

Print

Saniona: Tesomet in PWS study fully recruited

Saniona announced earlier today that the recruitment of Prader-Willi Syndrome (PWS)-patients, adolescents, has been completed.

Saniona has decided that the study will remain open for a few more weeks due to high interest from patients to participate in the study. The original plan was to include 10 – 15 PWS adolescents. Hence, we think it is likely that the second part of the study will include around 15 patients in total. We see it as positive that Tesomet has the chance to show safety and efficacy (weight loss and decreased hyperphagia) in the upper part of the intended patient population.

The study is a multi-center, randomized, placebo-controlled, and double-blind phase IIa trial. Treatment duration with Tesomet is 12 weeks. The company expects top-line data to be able to be presented in Q1’19. It is according to previous communication by the company and according to our timeline as well.

Download our latest Research Report from 2018-08-24

Download full report icon-download